These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 16221055

  • 1. Investigational agents for epithelial ovarian cancer.
    Muggia F, Kosloff R.
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):855-68. PubMed ID: 16221055
    [Abstract] [Full Text] [Related]

  • 2. Emerging role of pemetrexed in ovarian cancer.
    Tomao F, Panici PB, Frati L, Tomao S.
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1727-35. PubMed ID: 19954283
    [Abstract] [Full Text] [Related]

  • 3. Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?
    Tummala MK, Alagarsamy S, McGuire WP.
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1135-47. PubMed ID: 18588458
    [Abstract] [Full Text] [Related]

  • 4. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer.
    Sugarbaker PH.
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):15-24. PubMed ID: 19124999
    [Abstract] [Full Text] [Related]

  • 5. Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience.
    Carmignani CP, Sugarbaker PH.
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):477-87. PubMed ID: 15161446
    [Abstract] [Full Text] [Related]

  • 6. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
    Markman M.
    Trends Pharmacol Sci; 2008 Oct; 29(10):515-9. PubMed ID: 18760845
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report.
    Camci C, Sevinc A, Aslan Y, Kalender ME, Buyukberber S.
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):745-8. PubMed ID: 18504578
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. New and emerging intraperitoneal (IP) drugs for ovarian cancer treatment.
    Muggia FM.
    Semin Oncol; 2006 Dec; 33(6 Suppl 12):S18-24. PubMed ID: 17223446
    [Abstract] [Full Text] [Related]

  • 17. [Intraperitoneal chemotherapy for ovarian cancer].
    Noma J, Yoshida N.
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):885-90. PubMed ID: 18633214
    [Abstract] [Full Text] [Related]

  • 18. Chemotherapy in epithelial ovarian cancer.
    Pignata S, Cannella L, Leopardo D, Pisano C, Bruni GS, Facchini G.
    Cancer Lett; 2011 Apr 28; 303(2):73-83. PubMed ID: 21353386
    [Abstract] [Full Text] [Related]

  • 19. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.
    Markman M.
    Oncologist; 2007 Feb 28; 12(2):186-90. PubMed ID: 17296814
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.